COMMUNIQUÉS West-GlobeNewswire

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma
23/10/2026
62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the [...]
How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated
23/10/2026
Of the 106 peptide and nanobody drug conjugates in active development, roughly 63% are still preclinical, which places many of the decisions that shape manufacturability in the design phase. Cyclization, lipidation, [...]
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
23/10/2026
Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores [...]
KFSH Advances Gene Therapy for Sickle Cell Disease Using Patients’ Own Modified Stem Cells
23/10/2026
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is advancing gene therapy for sickle cell disease through a 2026 clinical trial that uses the patient’s [...]
Le KFSH réduit le délai d’attente pour un rendez-vous d’échocardiographie de 126 jours à un seul
23/10/2026
RIYAD, Arabie saoudite, 23 oct. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSH) a réduit le délai d’attente pour le premier rendez-vous d’échocardiographie disponible dans son [...]
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
23/10/2026
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒ ² MRI disease activity [...]
Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026
23/10/2026
Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet needs remain for [...]
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
23/10/2026
Company Announcement COPENHAGEN, Denmark; October 23, 2026 Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart [...]
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
23/10/2026
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib Vopimetostat [...]
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
23/10/2026
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, [...]
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
23/10/2026
HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory HQ-CT scores fell by Week 2 of dose escalation on ARD-101 and returned to near baseline within two [...]
KFSH Marks Four Decades of Cardiac Innovation, from One Cath Lab to an Integrated Heart Center
23/10/2026
RIYADH, Saudi Arabia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- What began with a single cardiac catheterization laboratory four decades ago has evolved into an advanced cardiovascular program at King Faisal Specialist Hospital [...]
Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
23/10/2026
PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Super Vision Technology: World’s first i-NYS implant for congenital nystagmus in a Chinese boy
23/10/2026
BEIJING, Oct. 23, 2026 (GLOBE NEWSWIRE) -- A 9-year-old boy has become the world's first patient to receive a newly approved implant to treat congenital nystagmus, in a procedure performed at Peking University People's [...]
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse
23/10/2026
Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease progression or death by 71% and risk of death by 40%, compared [...]
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
23/10/2026
Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone 1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints 1-3 Patients off Kisqali for a [...]
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
23/10/2026
Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated with progression-free survival and overall survival following immunotherapies including the [...]
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
23/10/2026
Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with [...]
Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
23/10/2026
Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery SYDNEY, AUSTRALIA, Oct. 23, 2026 (GLOBE NEWSWIRE) -- [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum